Myocarditis - Pipeline Review, H2 2018

Myocarditis - Pipeline Review, H2 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis - Pipeline Review, H2 2018, provides an overview of the Myocarditis (Cardiovascular) pipeline landscape.

Myocarditis is inflammation of the heart muscle. Myocarditis is an uncommon disorder that is usually caused by viral, bacterial, or fungal infections that reach the heart. Symptoms include chest pain, rapid or abnormal heartbeat, shortness of breath, at rest or during physical activity, fluid retention with swelling of legs, ankles and feet and fatigue. Treatment includes antibiotics, anti-inflammatory medicines to reduce swelling and diuretics to remove excess water from the body.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Myocarditis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Myocarditis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocarditis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocarditis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Myocarditis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocarditis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Myocarditis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocarditis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocarditis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocarditis (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocarditis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocarditis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myocarditis - Overview
Myocarditis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocarditis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocarditis - Companies Involved in Therapeutics Development
Apitope International NV
CEL-SCI Corp
Evotec AG
Swedish Orphan Biovitrum AB
Myocarditis - Drug Profiles
anakinra - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATX-MYO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OBR-5340 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides for Myocardial Infarction and Myocarditis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Coxsackievirus B3 3C Protease for Myocarditis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myocarditis - Dormant Projects
Myocarditis - Product Development Milestones
Featured News & Press Releases
Dec 11, 2017: Evotecs Academic Bridge LAB282 with Oxford University celebrating one year of impact
Nov 10, 2016: Evotec and Oxford create novel Partnership called LAB282
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Myocarditis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Myocarditis - Pipeline by Apitope International NV, H2 2018
Myocarditis - Pipeline by CEL-SCI Corp, H2 2018
Myocarditis - Pipeline by Evotec AG, H2 2018
Myocarditis - Pipeline by Swedish Orphan Biovitrum AB, H2 2018
Myocarditis - Dormant Projects, H2 2018

List Of Figures


Number of Products under Development for Myocarditis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Myocarditis - Pipeline Review, H2 2018

Myocarditis - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis - Pipeline Review, H2 2018, provides an overview of the Myocarditis (Cardiovascular) pipeline landscape.Myocarditis is inflammation

USD 2000 View Report

Myocarditis - Pipeline Review, H1 2018

Myocarditis - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Myocarditis - Pipeline Review, H1 2018, provides an overview of the Myocarditis (Cardiovascular) pipeline landscape.Myocarditis

USD 2000 View Report

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2018

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1)

USD 3500 View Report

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H2 2018

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Pipeline Review, H2 2018Phosphatidylinositol 4,5

USD 3500 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available